Performance of a Multianalyte ‘Rule-Out’ Assay in Pregnant Individuals With Suspected Preeclampsia
Authors:
- Maged M. CostantineMCMaged M. Costantine
- Baha SibaiBSBaha Sibai
- Allan T. BombardABAllan T. Bombard
- Mark SarnoMSMark Sarno
- Holly WestHWHolly West
- David M. HaasDHDavid M. Haas
- Alan T. TitaATAlan T. Tita
- Erin A.S. ClarkECErin A.S. Clark
- Kim BoggessKBKim Boggess
- Chad GrotegutCGChad Grotegut
- William GrobmanWGWilliam Grobman
- Emily J SuESEmily J Su
Open Access
- 1 July 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (7) , 1515-1524
Abstract
Background: The ability to diagnose preeclampsia clinically is suboptimal. Our objective was to validate a novel multianalyte assay and characterize its performance, when intended for use as an aid to rule-out preeclampsia. Methods: Prospective, multicenter cohort study of pregnant individuals presenting between 28 0/7 and 36 6/7 weeks’ with preeclampsia-associated signs and symptoms. Individuals not diagnosed with preeclampsia after baseline evaluation were enrolled in the study cohort, with those who later developed preeclampsia, classified as cases and compared with a negative control group who did not develop preeclampsia. Individuals with assay values at time of enrollment ≥0.0325, determined using a previously developed algorithm, considered at risk. The primary analysis was the time to develop preeclampsia assessed using a multivariate Cox regression model. Results: One thousand thirty-six pregnant individuals were enrolled in the study cohort with an incidence of preeclampsia of 30.3% (27.6%–33.2%). The time to develop preeclampsia was shorter for those with an at-risk compared with negative assay result (log-rank P P <0.0001]). The performance metrics for the assay to rule-out preeclampsia within 7 days of enrollment showed a sensitivity 76.4% (67.5%–83.5%), negative predictive value 95.0% (92.8%–96.6%), and negative likelihood ratio 0.46 (0.32–0.65). Assay performance improved if delivery occurred <37 weeks and for individuals enrolled between 28 and 35 weeks. Conclusions: We confirmed that a novel multianalyte assay was associated with the time to develop preeclampsia and has a moderate sensitivity and negative likelihood ratio but high negative predictive value when assessed as an aid to rule out preeclampsia within 7 days of enrollment. Registration: The study was registered on Clinicaltrials.gov (Identifier NCT02780414).Keywords
This publication has 26 references indexed in Scilit:
- Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected PreeclampsiaNew England Journal of Medicine, 2016
- The Role of Headache in the Classification and Management of Hypertensive Disorders in PregnancyObstetrics & Gynecology, 2015
- Global causes of maternal death: a WHO systematic analysisThe Lancet Global Health, 2014
- Hypertension in PregnancyObstetrics & Gynecology, 2013
- Quantifying the Added Value of a Diagnostic Test or MarkerClinical Chemistry, 2012
- Pre-eclampsia in low and middle income countriesBest Practice & Research Clinical Obstetrics & Gynaecology, 2011
- Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trialThe Lancet, 2009
- Latest Advances in Understanding PreeclampsiaScience, 2005
- Pregnancy-related mortality from preeclampsia and eclampsiaObstetrics & Gynecology, 2001
- Pre-eclampsia and serum antibodies to oxidised low-density lipoproteinThe Lancet, 1994